Clinical Research

1. Paediatric Hepatic International Tumour Trial (PHITT)
   Site Principal Investigator: Dr. Soh Shui Yen 
   


2. SIOP Renal Tumour Study Group (RTSG) (UMBRELLA Protocol)
   Site Principal Investigator: Dr. Prasad Iyer 
   


3. DAY101 in Paediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advanced Solid Tumours (FIREFLY-1)
   (ClinicalTrials.gov Identifier: NCT04775485) 
   Site Principal Investigator: Dr. Enrica Tan 
   


4. DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
   (ClinicalTrials.gov Identifier: NCT05566795) 
   Site Principal Investigator: Dr. Enrica Tan 
   


5. Repotrectinib in Paediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
   (ClinicalTrials.gov Identifier: NCT04094610) 
   Site Principal Investigator: Dr. Soh Shui Yen 
   


6. Comprehensive Genomic Profiling of Paediatric Brain and Solid Tumours (SPONC18B1)
   Site Principal Investigator: Dr. Mya Soe Nwe


7. Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in paediatric patients with relapsed or refractory neuroblastoma and other solid tumours
   (ClinicalTrials.gov Identifier: NCT05429502) 
   Site Principal Investigator: Dr. Soh Shui Yen 
   

1. CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy (SHCELL18P1)
   (ClinicalTrials.gov Identifier: NCT05648019) 
   Principal Investigator: Dr. Soh Shui Yen
   


2. Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T-cell Therapy
   (ClinicalTrials.gov Identifier: NCT05429905) 
   Principal Investigator: Dr. Michaela Seng 
   


3. Novel Adoptive Cellular Therapy with SARS-CoV-2 Specific T cells in Patients with Severe COVID-19
   (ClinicalTrials.gov Identifier: NCT04351659) 
   Principal Investigator: Dr. Michaela Seng 
   

1. Malaysia – Singapore Acute Lymphoblastic Leukaemia – Seq 2020
   (ClinicalTrials.gov Identifier: pending)
   Site Principal Investigator: A/Prof. Tan Ah Moy 
   


2. Asia Down Syndrome – Acute Lymphoblastic Leukaemia (DS-ALL) 2016
   (ClinicalTrials.gov Identifier: NCT03286634) 
   Site Principal Investigator: A/Prof. Tan Ah Moy 
   


3. Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory ALL
   (ClinicalTrials.gov Identifier: NCT02303821) 
   Site Principal Investigator: Dr. Prasad Iyer 
   


4. BH3 Profiling on ALL and AML Blasts to Direct Leukemia and Lymphoma Treatment
   Site Principal Investigator: Dr. Prasad Iyer 
   

1. PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Patients (PUP) With Severe Haemophilia A
   (ClinicalTrials.gov Identifier: NCT02615691) 
   Principal Investigator: Dr. Joyce Lam 
   


2. MUSFIH-PRO
   Principal Investigator: Dr. Joyce Lam 
   

1. Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
   (ClinicalTrials.gov Identifier: NCT02798471) 
   Site Principal Investigator: Dr. Joyce Lam 
   


2. Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network
   Site Principal Investigator: Dr. Joyce Lam 
   


3. International Epidemiological Study of Neonatal Purpura Fulminans
   Site Principal Investigator: Dr. Joyce Lam 
   


4. International Paediatric Thrombosis Network
   Site Principal Investigator: Dr. Joyce Lam 
   

The research arm of the Children's Cancer Foundation (CCF) Psychosocial Supportive Care Programme (PSCP) aims to explore and develop innovative interventions to address the psychosocial needs of children with cancer and their families in Singapore. Our ongoing research ensures that our support services are up-to-date with the best clinical practices, so that our patients and families receive the best possible care.

Translational research for childhood brain and solid tumours is critical in finding new and better ways to treat these diseases, while trying to minimize the harm caused by drugs, radiation or surgery. This requires an integrated approach and a high degree of collaboration between doctors and scientists. In this area, KKH, with its high volume of patients, works in cooperation with research centres within the SingHealth Duke-NUS cluster.

Using a translational research pipeline, we adopt a targeted approach to advance scientific findings from basic, to pre-clinical and early clinical development, and on to early phase clinical trials, for various paediatric brain and solid tumours. Given the wide variety of tumour types, the Programme has adopted a special focus on development of personalised medical management strategies through individualized molecular and phenotypic tests.

Current Initiatives:

Modeling, Analysis and Translational Therapeutics for Tumours of Childhood (MAT3CH)

This platform develops orthotopic patient-derived xenografts (PDX) and in vitro cell line models of paediatric brain and solid tumours, in order to facilitate molecular characterization and evaluation of novel therapies for these diseases. This programme facilitates the molecular characterization of paediatric solid tumours in Asian children for the identification of pathogenic molecular aberrations, comparisons of inter-population variations, and in-vivo evaluation of novel agents for translation into early-phase human trials.

BST programme achievements:

(a) Translational research

• Programme has published a total of 81 publications and peer-reviewed journals and 71 presentations as at end 2021.
• Programme has developed and launched 5 key new lab-developed tests specially catered for paediatric brain and solid tumours.
• Through local and international collaborations, resource hubs have been launched to share preclinical models of childhood brain and solid tumours that have been established under the Programme’s MAT3CH project since 2015.

The KKH BMTCT research laboratory conducts basic science investigations and generates preclinical and correlative research which will be of immediate translational use in the clinics. Our laboratory is situated in the Discovery Tower at Academia, which houses SingHealth’s research laboratories and experimental animal facilities, within the vicinity of Duke-NUS Medical School. The vision is for a seamless circuit from innovation and discovery to animal in vivo studies and finally to the bedside, with robust correlative platforms and generating more areas of research. We aim to increase collaborations and exchanges with other centres to advance transplantation and cellular therapy in Singapore and beyond.

Some of the Programme's collaborations:

• External: NCCS Cancer Discovery Hub and NCCS Laboratory of Cell Therapy and Cancer Vaccines, Health Sciences Authority, Cell Therapy Facility, NUH Stem Cell Laboratory
• Internal: Brain and Solid Tumour Programme

Laboratory Journals:

W Leung, TG Soh, YC Linn, JGH Low, JS Loh, M Chan, WJ Chng, LP Koh, ML Poon, KP Ng, CH Kuik, TT Tan, LK Tan, MS Seng. Rapid production of clinical-grade SARS CoV-2 specific T cells. Adv Cell Gene Ther. 2020 Oct; 3(4):e101.
DOI:10.1002/acg2.101 PMID 32838213

For more information, visit our Blood and Marrow Tansplant and Cellular Therapy Centre via this Link